Suppliers and packagers for SKYLA

SKYLA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bayer Hlthcare	SKYLA	levonorgestrel	SYSTEM;INTRAUTERINE	203159	NDA	Bayer HealthCare Pharmaceuticals Inc.	50419-422-01	1 INTRAUTERINE DEVICE in 1 CARTON (50419-422-01)	2013-01-11
Bayer Hlthcare	SKYLA	levonorgestrel	SYSTEM;INTRAUTERINE	203159	NDA	Bayer HealthCare Pharmaceuticals Inc.	50419-422-08	1 INTRAUTERINE DEVICE in 1 CARTON (50419-422-08)	2013-01-11

Skyla Drug Supply Chain Analysis

Last updated: February 19, 2026

This report details the key suppliers and the structural framework of the supply chain for Skyla, a pharmaceutical product. The analysis focuses on the manufacturing, active pharmaceutical ingredient (API) sourcing, and packaging components critical to Skyla's production.

Who are the Primary Manufacturers of Skyla?

The manufacturing of Skyla is primarily handled by Bayer AG and its contract manufacturing organizations (CMOs). Bayer AG is the originator and holds the marketing authorization for Skyla. The company utilizes its internal manufacturing facilities and partners with specialized CMOs to ensure production volume and compliance with Good Manufacturing Practices (GMP).

• Bayer AG Manufacturing Sites: Bayer operates global manufacturing facilities that may contribute to Skyla production. Specific site allocation for Skyla is proprietary but adheres to stringent quality control and regulatory standards.
• Contract Manufacturing Organizations (CMOs): Bayer engages CMOs for specific stages of production, including sterile filling, lyophilization (if applicable to Skyla's formulation), and final product assembly. These CMOs are vetted through rigorous qualification processes to ensure alignment with Bayer's quality and regulatory requirements. Examples of CMOs that could be involved in such sterile injectable drug manufacturing include Lonza, Catalent, and Siegfried AG. The specific engagement with CMOs for Skyla is not publicly disclosed.

Where are the Active Pharmaceutical Ingredients (APIs) for Skyla Sourced?

The active pharmaceutical ingredient for Skyla is Levonorgestrel. Sourcing of Levonorgestrel is a critical component of the supply chain, requiring suppliers with the capability to produce high-purity APIs under cGMP conditions.

• Key API Supplier Profiles: While specific supplier names are confidential business information, pharmaceutical companies typically source APIs from specialized chemical manufacturers. These suppliers must demonstrate robust quality management systems, regulatory compliance (e.g., FDA, EMA inspected facilities), and secure supply chain integrity.
  • Potential API Suppliers: Companies with established expertise in steroid hormone synthesis are likely candidates. These include but are not limited to:
    • Ashland Global Holdings Inc.: Offers a broad range of pharmaceutical ingredients and services, including API manufacturing.
    • Evonik Industries AG: A specialty chemicals company with significant pharmaceutical ingredient offerings.
    • Pfizer CentreOne: The contract manufacturing division of Pfizer, capable of producing complex APIs.
  • Geographic Diversification: API sourcing often involves geographically diversified suppliers to mitigate supply chain risks and ensure business continuity. This can include suppliers in Europe, North America, and Asia.
• API Specifications and Quality Control: Levonorgestrel used in Skyla must meet stringent pharmacopoeial standards (e.g., USP, EP). This includes specifications for purity, impurity profiles, particle size distribution, and polymorphic form. Robust analytical testing and validation are conducted by both the API supplier and Bayer.

What are the Packaging and Device Component Suppliers for Skyla?

Skyla is an intrauterine device (IUD) that contains Levonorgestrel. The supply chain for Skyla extends to the specialized components required for the device itself and its sterile packaging.

Device Components:

The IUD structure, including the T-body and the drug-eluting component, requires precision manufacturing.

• Polymeric Materials: The T-body is typically made from a medical-grade thermoplastic, such as polyethylene or polypropylene. These materials must be biocompatible, inert, and capable of being molded into precise shapes. Suppliers in this segment often specialize in medical-grade polymers.
• Drug Reservoir/Membrane: The mechanism by which Levonorgestrel is released involves a specific design that incorporates the API. This could involve a membrane or a reservoir system. Suppliers for these components need expertise in controlled-release technologies and materials compatible with Levonorgestrel.
• Insertion Catheter Components: The insertion system requires plastic components, filaments, and potentially specialized lubricants that are safe for medical use and facilitate the insertion procedure.

Packaging Components:

Sterile packaging is paramount to maintaining the integrity and sterility of Skyla from the point of manufacture to patient use.

• Primary Packaging (Sterile Pouch):
  • Materials: Typically comprises medical-grade films and laminates (e.g., PET, PE, aluminum foil layers) designed to provide a barrier against moisture, light, and microbial contamination.
  • Manufacturers: Companies like Amcor, Berry Global, and Sealed Air Corporation are major suppliers of medical device packaging solutions, offering customizable pouches and films with validated sterilization resistance.
• Secondary and Tertiary Packaging:
  • Materials: Cardboard, plastics, and other materials for outer boxes, shipping containers, and labeling.
  • Manufacturers: General packaging material suppliers are involved at this stage.

What is the Regulatory Framework Governing Skyla's Supply Chain?

The supply chain for Skyla is subject to extensive regulatory oversight by health authorities worldwide.

• Good Manufacturing Practices (GMP): All manufacturing facilities involved in producing Skyla or its components must comply with cGMP regulations as mandated by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This ensures product quality, safety, and efficacy.
• Drug Master Files (DMFs): API suppliers typically maintain DMFs with regulatory authorities. These confidential documents provide detailed information about the manufacturing process, facilities, and controls for the API. Pharmaceutical companies reference these DMFs in their marketing authorization applications.
• Quality Agreements: Bayer establishes comprehensive quality agreements with its API suppliers and CMOs. These legally binding documents define the responsibilities of each party concerning quality control, testing, change management, and regulatory compliance.
• Supplier Audits and Qualification: Bayer conducts regular audits of its critical suppliers to ensure ongoing compliance with GMP and quality standards. This qualification process is a continuous element of supply chain management.
• Serialization and Traceability: Regulations like the U.S. Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD) mandate serialization and traceability of pharmaceutical products. Skyla's supply chain must incorporate systems to track products throughout distribution to prevent counterfeiting and ensure authenticity.

Key Takeaways

The Skyla supply chain is a multi-faceted operation reliant on specialized manufacturing expertise for both the drug product and the medical device component. Key elements include:

• Bayer AG's Central Role: Bayer AG directs manufacturing, either internally or through qualified contract partners.
• API Sourcing: Levonorgestrel is sourced from chemical manufacturers adhering to strict cGMP and quality standards. Geographic diversification is likely employed.
• Device and Packaging Specialization: Precision manufacturing for the IUD device and advanced sterile packaging solutions are critical, involving suppliers with expertise in medical-grade polymers and barrier films.
• Rigorous Regulatory Compliance: The entire supply chain operates under a stringent global regulatory framework, including GMP, quality agreements, and traceability requirements.

Frequently Asked Questions

1. How does Bayer ensure the quality and consistency of Levonorgestrel API from its suppliers?

Bayer implements a comprehensive supplier qualification program that includes rigorous audits of supplier facilities and quality systems. Quality agreements are established, defining specific testing protocols, release specifications, and change control procedures for the API. Batch-to-batch testing by Bayer also verifies API quality upon receipt.

2. What are the typical lead times for sourcing specialized medical device components for an IUD like Skyla?

Lead times for specialized medical device components can vary significantly but often range from several weeks to several months. This depends on the complexity of the component, the supplier's current production capacity, material availability, and the need for custom tooling or qualification processes.

3. Can counterfeit Skyla devices enter the legitimate supply chain?

The risk of counterfeit products is a constant concern in pharmaceutical supply chains. Regulatory measures like serialization and track-and-trace systems, alongside robust distribution controls and vigilance programs by manufacturers and distributors, are designed to mitigate this risk.

4. What is Bayer's strategy for managing supply chain disruptions for Skyla?

Bayer employs supply chain resilience strategies, which typically include qualifying secondary suppliers for critical raw materials and components, maintaining strategic inventory levels, and developing contingency plans for manufacturing. Diversification of manufacturing sites and geographic sourcing also plays a role.

5. What are the sterilization methods used for Skyla and its packaging?

The specific sterilization method for Skyla and its packaging is determined by the materials used and the product's stability. Common methods for medical devices and sterile packaging include gamma irradiation, ethylene oxide (EtO) sterilization, and potentially steam sterilization for certain components, all validated to ensure microbial inactivation and material integrity.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/good-manufacturing-practice-gmp

[2] European Medicines Agency. (n.d.). Manufacturing of medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory-information/manufacturing-medicines

[3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/drug-master-files-dmfs

[4] U.S. Food and Drug Administration. (n.d.). Drug Supply Chain Security Act (DSCSA). Retrieved from https://www.fda.gov/drugs/drug-supply-chain-act-dscsa/drug-supply-chain-security-act-dscsa

[5] European Commission. (n.d.). Medicinal products - Falsified medicines. Retrieved from https://health.ec.europa.eu/medicinal-products/falsified-medicines_en